Allstate Corporation’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Allstate Corporation’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,943	Closed	-$334K	–	727
2021 Q2	$334K	Sell	8,943 -4,481	-33%	-$137K	0.01%	628
2021 Q1	$343K	Hold	13,424	–	–	0.01%	639
2020 Q4	$296K	Hold	13,424	–	–	0.01%	623
2020 Q3	$241K	Buy	13,424 +1,390	+12%	+$28.8K	0.01%	616
2020 Q2	$306K	Buy	12,034 +37	+0.3%	+$797	0.01%	576
2020 Q1	$220K	Buy	+11,997	New	+$233K	0.01%	574

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Allstate Corporation's DRNA Position: Q3 2021 in Review

Allstate Corporation sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 8,943 shares — an estimated $334K sold.

Allstate Corporation first reported a position in DRNA in Q1 2020 and held it in 6 quarters. The position peaked at $343K in Q1 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Allstate Corporation reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Allstate Corporation sold 8,943 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $334K.
Allstate Corporation first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2020 and held it in 6 quarters.
Allstate Corporation's Dicerna Pharmaceuticals, Inc. position peaked at $343K in Q1 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Allstate Corporation's 13F filing for Q3 2021, filed 15 Nov 2021.